The national healtheare security administration has carried out six batches and seven rounds of drug centralized volume-based procurement (VBP). The sixth batch of insulin procurement is the first time that national volume-based procurement (NVBP) has expanded the field from chemical drugs to biopharmaceuticals. It intends to review the process of national drug volume-based procurement, briefly describe the current national regulation and approval of biosimilar drugs, analyze the policy and results of both Insulin Wuhan VBP and Insulin NVBP, and finally provide relevant policy thinking and suggestions for national volume-based procurement in the field of biopharmaceuticals.